B7-H3 (CD276): an actionable therapeutic target and prognostic biomarker across human malignancies
{{output}}
Immune checkpoint protein B7-H3 (CD276) has garnered increasing attention as a cancer immunotherapy target. Despite the absence of a definitively identified receptor, B7-H3 is implicated in multiple mechanisms of tumor progression. As a cancer biomarker, it is... ...
